New CE-IVD Molecular Diagnostic Assays to Detect a Range of Infections

Thermo Fisher Scientific and ALPCO-GeneProof have joined forces to introduce 37 CE-IVD molecular diagnostic assays to the market. The TaqPath Menu| GeneProof PCR Kits are designed to be user-friendly on a wide range of qPCR instruments and can detect a variety of genetic diseases and pathogens, including sexually transmitted, respiratory, and bloodborne infections. The kits will be launched in stages, with the first panel, which will detect bloodborne and sexually transmitted infections (STIs) such as herpes simplex virus, chlamydia, human papillomavirus (HPV), gonorrhoea, and human immunodeficiency virus (HIV), to be released in early 2023. The kits will help laboratories perform more tests quickly and make tools easier to use, allowing them to test for the diseases they need without having to switch out different instruments. The kits will be launched in select European and Latin American countries, with expansion into additional countries in the Middle East, Africa, and Asia throughout 2024.

The partnership between Thermo Fisher Scientific and ALPCO-GeneProof combines Thermo Fisher's robust supply chain and support systems, versatile qPCR instruments, and molecular workflow solution with ALPCO-GeneProof's efficient and powerful assays. The kits will provide a broad range of reliable and simple PCR-based testing to help diagnose infections, and they will help labs work with easy-to-use kits for a fast workflow implementation in routine analysis. The kits will also enable labs to be flexible and choose pathogens of interest to deliver fast and targeted results from a patient sample to physician request.

More information online